GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 301-312 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Conforti A; Cifuentes-González C; Agrawal KR; Agrawal R

Jan 1, 2026

2025CrossrefDirectly related0 citations

Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action

Aparna Sinha

Dec 15, 2025Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action

2025CrossrefDirectly related21 citations

Efficacy and Safety of <scp>GLP</scp> ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian <scp>NMA</scp>

Binayak Sinha; Samit Ghosal

Nov 1, 2025Obesity

2025Semantic ScholarDirectly related75 citations

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists

Tyson S. Barrett; Juliane O. Hafermann; Shannon Richards; Keith LeJeune; George M. Eid

Sep 17, 2025JAMA Surgery8 influential

2025OpenAlexDirectly related160 citations

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Sean Wharton; Louis J. Aronne; Adam Stefański; Nasreen Alfaris; Andreea Ciudin; Koutaro Yokote; Bruno Halpern; Alpana P. Shukla; Chunmei Zhou; Lisa Macpherson; Sheryl Allen; Nadia N. Ahmad; Suzanne Klise

Sep 16, 2025New England Journal of Medicine

2025OpenAlexDirectly related37 citations

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes

Pareeta Kotecha; Wenxi Huang; Ya-Yun Yeh; Valerie Martino Narvaez; Darlene Adirika; Huilin Tang; Angelina Bernier; Sarah Westen; Steven M. Smith; Jiang Bian; Jingchuan Guo

Sep 15, 2025Archives of Pediatrics and Adolescent Medicine

2025CrossrefDirectly related0 citations

<b>Semaglutide-Associated Severe Gastrointestinal Intolerance and Hepatic Granulomas: A Case Report</b>

Aqsa Khan; Badeeya Rashid; Fareedullah; Sibghatullah

Sep 12, 2025Journal of Diabesity

2025Semantic ScholarDirectly related8 citations

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.

Andrijana Koceva; A. Janež; M. Jensterle

Sep 1, 2025Best practice & research. Clinical endocrinology & metabolism1 influential

2025Semantic ScholarDirectly related18 citations

Adverse drug reaction patterns of GLP‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database

Tae Hyeon Kim; Kyeongmin Lee; Seoyoung Park; Jiyeon Oh; Jaeyu Park; Hyesu Jo; Hayeon Lee; Jaehyeong Cho; Xuerong Wen; Hanseul Cho; Sunyoung Kim; D. Yon

Apr 2, 2025Diabetes, obesity and metabolism1 influential

2025OpenAlexDirectly related70 citations

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

Nadia J Abbass; Raya Nahlawi; Jacqueline K. Shaia; Kevin Allan; David C. Kaelber; Katherine E. Talcott; Rishi P. Singh

Feb 25, 2025American Journal of Ophthalmology

2025Semantic ScholarDirectly related13 citations

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon

R. Abdelrahman; T. Musa; I. Arbab; Mohsen Hussein Suliman; E. O. Ahmed; Asma Noureldaim Mohamed; Hassan Hussein Musa; Mohammed M. Jalal; Sahar Ibrahim Gasmallah

Jan 1, 2025Journal of Obesity1 influential

2025PubMedDirectly related

Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.

Shetty S; Bannur Karunakara M; Kristipati RR; Kalthur G; Kumari S

Jan 1, 2025F1000Research